Guselkumab improves long-term histologic outcomes in patients with ulcerative colitis
NASHVILLE, Tenn. — The dual-acting interleukin-23 inhibitor guselkumab improved histologic outcomes in patients with moderately to severely active ulcerative colitis over a 3-year span, according to a presenter here. While some clinical trials have shown histologic outcomes in patients with UC, researchers…